The analysis of the PCSF subnetwork showed that proteins associated with the EGFR and APOA1 pathways were generally decreased in serum samples taken from subjects with metabolic syndrome and MASLD at the end of 4-week DDDF compared with the serum collected before 4-week DDDF (Fig. 4A). This evidence concerns the gene EGFR and metabolic dysfunction-associated steatotic liver disease.